Likuiditas cepet Pasithea Therapeutics Corp (KTTA)

Pasithea Therapeutics (KTTA) is implementing automated systems for clinical data analysis and molecule screening, while simultaneously building a foundation for personalized mental disorder treatment through the patenting of its developments. The current metric stands at 25.59. This chart of share prices on GURU.Markets confirms the resilience of the business, which leverages its own clinic network and unique CNS therapy molecules to minimize customer churn.

The quick ratio assesses a company's ability to meet short-term obligations using its most liquid assets. By analyzing current quick liquidity, an investor evaluates the ratio of cash and accounts receivable to liabilities, excluding low-liquidity inventories. The trend of this metric reflects operational resilience and the quality of capital management. For Pasithea Therapeutics (KTTA), this is critical, as financial stability depends directly on patient inflow and the success of developments in PTSD therapy.